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Abstract: Streptococcus pneumoniae is a common pathogen that causes various infections, 
such as sepsis and meningitis. A major pathogenic factor of S. pneumoniae is the 
cholesterol-dependent cytolysin, pneumolysin. It produces cell lysis at high concentrations 
and apoptosis at lower concentrations. We have shown that sublytic amounts of 
pneumolysin induce small GTPase-dependent actin cytoskeleton reorganization and 
microtubule stabilization in human neuroblastoma cells that are manifested by cell 
retraction and changes in cell shape. In this study, we utilized a live imaging approach to 
analyze the role of pneumolysin’s pore-forming capacity in the actin-dependent cell shape 
changes in primary astrocytes. After the initial challenge with the wild-type toxin, a 
permeabilized cell population was rapidly established within 20–40 minutes. After the 
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initial rapid permeabilization, the size of the permeabilized population remained unchanged 
and reached a plateau. Thus, we analyzed the non-permeabilized (non-lytic) population, 
which demonstrated retraction and shape changes that were inhibited by actin 
depolymerization. Despite the non-lytic nature of pneumolysin treatment, the toxin’s lytic 
capacity remained critical for the initiation of cell shape changes. The non-lytic 
pneumolysin mutants W433F-pneumolysin and delta6-pneumolysin, which bind the cell 
membrane with affinities similar to that of the wild-type toxin, were not able to induce 
shape changes. The initiation of cell shape changes and cell retraction by the wild-type 
toxin were independent of calcium and sodium influx and membrane depolarization, which 
are known to occur following cellular challenge and suggested to result from the ion 
channel-like properties of the pneumolysin pores. Excluding the major pore-related 
phenomena as the initiation mechanism of cell shape changes, the existence of a more 
complex relationship between the pore-forming capacity of pneumolysin and the actin 
cytoskeleton reorganization is suggested. 
Keywords: pneumolysin; pore formation; cytoskeleton 
 
1. Introduction 
Streptococcus pneumoniae (pneumococcus) is a human pathogen that causes life-threatening 
diseases, such as pneumonia, sepsis, and the most common form of bacterial meningitis. Disease rates 
are particularly high in young children, elderly people and immunosuppressed patients [1]. New strains 
that are resistant even against potent reserve antibiotics continuously occur. Not only developing but 
also highly developed countries are confronted with the threat of S. pneumoniae infection [2]. Bacterial 
meningitis is associated with high lethality and neurological disability in the surviving patient.  
Only 30% of the infected patients overcome the disease, and 30% of these survivors are affected by 
long term sequelae [3], including mental retardation, learning impairment and focal neurological 
deficits (e.g., hearing loss). The acute infection is accompanied by blood vessel inflammation, CNS 
necrosis, neuronal loss and general inflammation of brain tissue [4].  
Proper functioning of adult neurons in the brain is known to be crucial for learning and memory [5], 
and it is believed that alterations in learning and memory are a common consequence of toxic factor 
exposure [6]. Neuronal function and brain homeostasis in turn are strongly dependent on functional 
glial cells, such as astrocytes, oligodendrocytes and microglia. Whereas microglia are small, 
highly-motile macrophage-like brain components, astrocytes are big star-shaped, process-bearing cells, 
that constitute up to 50% of the volume of most brain areas, and outnumber neurons by over 
fivefold [7]. Connected to each other via gap junctions, and thereby forming a glial syncytium, they 
fence in neurons and oligodendrocytes. Astrocyte end-feet are also a major component of the 
blood-brain barrier together with an endothelial cell layer that controls the exchange of substances 
between blood and brain [8,9]. Astrocytes play a critical role in synapse mediator uptake and recycling 
in the brain as well [10]. Dysfunction of astrocytes and microglia contributes to dysfunction of neurons 
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and vice versa. Thus, not only neuronal alterations, but also damage to or disturbed functioning of glial 
cells should be considered to occur during the course of bacterial meningitis [11]. 
S. pneumoniae carries at least eight specific proteins, which determine its pathogenicity. A major 
virulence factor is the protein toxin pneumolysin (PLY), which is produced by virtually all clinical 
isolates [12]. PLY is a cytosolic protein that is predominantly released upon bacterial lysis [13], 
although other mechanisms are also suggested [14]. It belongs to the family of cholesterol-dependent 
cytolysins (CDC). The hallmark of these cytolysins is their binding to the cell membrane in a 
cholesterol-dependent manner and penetration through the host’s membrane by producing a pore. The 
structural information concerning PLY has been determined by fitting the structure of 
perfringolysin O (PFO) to PLY [15]. PLY consists of four domains, arranged in an asymmetric 
manner. The currently accepted pore formation model describes PLY monomers binding to membrane 
cholesterol with their C-terminal domain 4 via a Trp-rich motif to form a prepore. PLY penetrates the 
membrane following the unfolding of the molecule and by inserting domain 3 into the lipid 
environment of the membrane [15,16]. Thus, a barrel-structured pore with a size of ~260 Å is formed, 
which leads to membrane collapse and cell lysis.  
Most of the structural biology studies use PLY concentrations of 10 µg/mL to 200 µg/mL and test 
its effects on artificial liposomes, artificial membranes or erythrocytes [16–18]. In pathological 
conditions, such as S. pneumoniae meningitis, the concentration on PLY in the cerebrospinal fluid 
(CSF) of patients never exceeds 0.2 µg/mL [19]. In an effort to study PLY effects in the context of the 
immune system, non-pore forming mutants were developed. Two of them—delta6-PLY and 
W433F-PLY—were used in this work. These variants are incapable of lytic pore formation at 
pathologically relevant concentrations. At high concentrations, W433F-PLY shows 1% hemolytic 
activity when compared to the WT-PLY, but should be capable of forming ion channel-like pores at 
concentrations of 1–10 µg/mL in planar lipid bilayers (PLB) [16]. Delta6-PLY is incapable of  
forming pores, as the mutation is located between domain 1 and 3, thus losing the capability to 
oligomerize [17,20]. Here, two amino acids are deleted, A146 and R147 [17]. It remains, however, 
unclear whether lytic pore formation and micropore (possessing ion channel-like properties) formation, 
both of which are properties of CDCs, are mechanistically similar or different phenomena. 
Many bacterial toxins have developed an evolutional ability to either directly or indirectly  
(by altering the modifying biochemical cascades) reorganize cellular actin [21]. One final effect of 
these changes is a change in the cellular motility and displacement [22], which leads to improved 
bacterial entrance through tissue barriers. We have shown that PLY leads to the activation of the small 
GTPases RhoA and Rac1 in the SH-SY5Y human neuroblastoma cell line [22]. In rodent meningitis 
models, PLY-deficient strains exhibit a reduced virulence, characterized by strongly impaired brain 
invasion and CSF distribution [23,24]. Obviously, PLY plays an important role in the early infection 
development [25] and demonstrates immunomodulatory effects [26]. Unfortunately, large amounts of 
the cell biology features of PLY are studied in cell lines, but not in primary cells [22,27], which makes 
translation of results to primary cell systems complicated. Furthermore, it remains unclear whether 
these effects are seen in a similar manner in primary brain cells and whether pore formation is required 
for these changes or not. To clarify the role of pore formation in the reorganization of the actin 
cytoskeleton, as well as to translate the finding to primary brain cells, we investigated the effects of 
WT-PLY and the two non-lytic mutants delta6-PLY and W433F-PLY in primary astrocytes. 
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2. Materials and Methods 
2.1. Pneumolysin Preparation  
W433F-PLY [16] (partially non-lytic (1% of wild-type) mutant) is expressed in Escherichia coli 
XL-1 cells (Stratagene, Cambridge, UK) and purified by hydrophobic interaction chromatography as 
described previously [17,28]. The non-toxic delta6 version of the plasmid was constructed by site-directed 
mutagenesis (QuikchangeSDMKit, Stratagene) of pET33bPLY [29] using primers 23B [30] and 23C [30] 
to introduce a deletion of alanine at position 146 and arginine at position 147. WT-PLY and  
delta6-PLY were then expressed in E. coli BL21 (DE3) cells (Stratagene) and purified using nickel 
affinity chromatography and anion exchange chromatography, as previously described [30]. All 
purified proteins were tested for the presence of contaminating Gram-negative LPS using the 
colorimetric LAL assay (KQCL-BioWhittaker, Lonza, Basel, Switzerland). All purified proteins had 
<0.6 Endotoxin Units (EU)/g protein. The primers were as follows: 
23B—GGTCAATAATGTCCCAATGCAGTATGAAAAAATAACGGCTC 
23C—GAGCCGTTATTTTTTCATACTGCATTGGGACATTATTGACC 
2.2. Cell Cultures, Vital Staining, Live Imaging 
Primary astrocytes were prepared from the brains of postnatal day 4–6 newborn Sprague-Dawley 
(SD) rats or C57BL/6 mice and cultured as a mixed culture as previously reported [11] in DMEM 
medium (GibcoBRL, Invitrogen GmbH, Karlsruhe, Germany), supplemented with 10% fetal calf 
serum (FCS) (PAN Biotech GmbH, Aidenbach, Germany) and 1% penicillin/streptomycin (GibcoBRL) 
in 75 cm
2
 poly-L-ornithine (Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany) coated cell culture 
flasks (Sarstedt AG & Co., Nuembrecht, Germany). At day 10–14 after seeding, the astrocytes were 
trypsinized and seeded in chamber slides, coated with poly-L-ornithine.  
For live imaging experiments, the cells were incubated in pH-insensitive L-15 Leibovitz medium 
(Invitrogen) at 37 °C with propidium iodide or YOYO-1 green chromatin stain in the medium,  
thus staining permeabilized cells, and Hoechst 33342, staining the nuclei of all cells (all stains  
diluted 1:1,000 of a 1 mg/mL stock, Invitrogen). The cells were visualized on an Olympus Cell^M 
Imaging system using 10× and 20× dry objectives (Olympus Deutschland GmbH, Hamburg, 
Germany). Membrane potential was visualized by cell incubation with the potential-sensing 
fluorescent dye DiBac4(5) (bis-(1,3-dibutylbarbituric acid) pentamethine oxonol; 500 nM, Invitrogen) 
using an Olympus Cell^M system or a Leica LSM SP5 microscope (Leica Microsystems Heidelberg 
GmbH, Mannheim, Germany). The signal background was measured for 5 min before further treatments.  
Astrocyte transduction with GFP tagged to the membrane localization fragment, was performed 
using a baculovirus vector system (Organelle Lights expression system, Invitrogen) according to 
manufacturer’s instructions. 
Confocal imaging was performed using a heated chamber system at ~37 °C, acquiring images  
every 2 minutes (DiBAC4(5)) at an image resolution of 1024 × 1024 pixel. 
In all experiments, cells and tissues were treated with PLY in serum-free medium. In live imaging 
experiments, the cells were starved for 60 min–12 h before exposure to the toxin. Cell displacement 
and retraction was analyzed by simultaneous observation of toxin-treated and mock-treated cells with 
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automatic repositioning of the microscopic stage with a precision of 1 µm (according to 
manufacturer’s instructions) per move. The cells were tracked by ImageJ (version 1.43 for Windows, 
National Institute of Health, Bethesda, MD, USA), using a stack tacking plug-in from the microscopy 
plug-in package of Tony Collins (http://rsbweb.nih.gov/ij/plugins/mbf-collection.html).  
2.3. Special Buffers and Treatments 
Membrane hyperpolarization of astrocytes was achieved by exposure to 200 mM sucrose (Carl 
Roth, Karlsruhe, Germany) [31]. The effect of sucrose in our experimental system was titrated by 
continuous monitoring with DiBac4(5) until stable and reproducible hyperpolarization was achieved  
at 200 mM sucrose. In calcium (Ca)-free buffer experiments, the cells were exposed to the toxin, in a 
buffer containing 135 mM NaCl, 2.5 mM MgCl2, 4mM KCl, 5 mM Hepes (all from Carl Roth), 
pH = 7.3. Sodium-free buffer contained 135 mM tetramethylamonium chloride (TMA; from Carl 
Roth), 2.5 mM MgCl2, 4 mM KCl, 5 mM Hepes, pH = 7.3. Thapsigargin (3 µM, Enzo Life Sciences 
GmbH, Lörrach, Germany) was applied for 30 min in Ca-free buffer, to empty the intracellular 
depots [32] before further treatment was performed. In cholesterol inactivation experiments, PLY was 
treated with cholesterol (Sigma) in a ratio of 1:10 (toxin:cholesterol, w/w) in PBS for 30 min at 37 °C, 
as the cholesterol solvent (ethanol, Carl Roth) never exceeded 0.1% in the inactivation solution. In 
some experiments, the treatment medium was collected after 30–60 min challenge of the cells, PLY 
was inactivated by cholesterol and the medium was transferred to a new test culture in order to study 
the role of products, released after cell lysis.  
2.4. Immunohisto- and Immunocytochemistry 
The cells were fixed with 4% paraformaldehyde in PBS (all from Sigma). They were permeabilized 
with 0.1% Triton X-100 (Carl Roth) for 10 min at room temperature (RT), blocked with 4% BSA in 
PBS for 30 min RT and incubated with primary antibody against vinculin (Santa Cruz) or with 
phalloidin-Alexa488 (Invitrogen) for 1 h RT. Goat anti-mouse Fab fragment, labeled with FITC or 
Cy3 (1:200; Dianova, Hamburg, Germany) were used to visualize the primary antibody. In some 
experiments, the nuclei were stained with Hoechst chromatin stain. All samples were preserved with 
Mowiol (Carl Roth, Germany). Samples were visualized with a Leica LSM SP5 microscope, using a 
63× oil immersion objective. Image processing and analysis was performed by ImageJ. For focal 
adhesions analysis, equivalent imaging areas in the middle of each culture well (4-well chamber slides, 
Nunc, Thermo Electron LED GmbH, Langenselbold, Germany) with equivalent cell density were 
visualized, as microglia cells (isolectin B4-positive (isolectin B4 from Sigma)) were excluded and only 
astrocytes (as judged by positive anti-GFAP (Sigma) immunostaining) were analyzed. All measurements 
were performed on a slice at the bottom of the cells after obtaining a complete confocal z-stack of each 
imaging field. 
2.5. Protein Biochemistry Analysis 
In spectrophotometric experiments, tryptophan fluorescence of recombinant PLY (0.5 µM) was 
analyzed in a buffer comprising 50 mM Tris acetate (pH = 7.2) and 100 mM potassium acetate. The 
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fluorescence spectrum between 300 and 400 nm following excitation at 280 nm was analyzed using a 
Perkin Elmer LS50B (Perkin Elmer, Inc., Waltham, MA, USA) spectrophotometer, before and after 
the addition of cholesterol (or ethanol (both from Sigma) as a solvent control) in a ratio of 1:1 (w:w) 
cholesterol:PLY.  
In Western blot experiments, samples containing equal amounts of proteins were electrophoresed 
on SDS-PAGE gradient gels (4–12% acrylamide, Anamed, Germany). The separated proteins were 
transferred via semi-dry blotting to PVDF Imobilion-P transfer membrane (Millipore, Germany). 
Membranes were blocked using 3–5% non-fat milk (Carl Roth, Germany) and were incubated with 
anti-PLY antibody (Abcam Inc., Cambridge, MA USA) (1:400). After incubation with a horseradish 
peroxidase-conjugated rabbit anti-mouse antibody (Jackson Immuno Research, USA) blots were 
detected using ECL Plus Western Blotting Reagent (GE Healthcare, Germany) and a the Fluorchem Q 
machine (Alpha Innotech, Germany).  
Primary rat astrocytes were mechanically homogenized by passing them through a G19 needle  
in 200 µL lysis buffer (containing 250 mM sucrose and a protease inhibitor mix (Roche Applied 
Science, Mannheim, Germany). The homogenate was centrifuged at 900 g for 10 min at 4 °C. The 
resulting supernatant was centrifuged at 110,000 g for 75 min at 4 °C. The crude membrane pellet was 
resuspended in lysis buffer.  
2.6. Lactate Dehydrogenase (LDH) Test 
The lactate dehydrogenase detection kit (Roche Diagnostics GmbH, Mannheim, Germany) was 
used in some experiments, according to the manufacturer’s instructions to assess toxicity and cell lysis. 
2.7. Planar Lipid Bilayer (PLB) 
The planar lipid bilayer experiments were carried out as previously described [33]. Membranes 
were formed from a 1% (w/v) solution of diphytanoyl phosphatidylcholine (PC) (Avanti Polar Lipids, 
Alabaster, AL, USA) in n-decane. 25% cholesterol (w/w) was added to simulate cholesterol content in 
an astrocyte membrane. The toxin (0.1 µg/mL–0.3 µg/mL) was added to the aqueous phase after the 
membrane had turned black. The membrane current was measured with a pair of Ag/AgCl electrodes 
with salt bridges switched in series by a voltage source and a highly sensitive current amplifier 
(Keithley 427, Keithley Electronics, Garland, TX, USA). The temperature was maintained at 20 °C 
throughout. 
2.8. Evaluation and Statistics 
Image processing and image analysis were performed using ImageJ software (version 1.43 for 
Windows, National Institute of Health, Bethesda, MD, USA). Statistical analysis was performed on 
GraphPad Prism 4.02 for Windows (GraphPad Software Inc., La Jolla, CA, USA). Statistical tests 
included a Mann-Whitney U-test (comparing 2 groups differing with one parameter at a time) or 
one-way ANOVA with Bonferroni post-test (comparing 3 or more groups, differing with one 
parameter at a time). 
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3. Results and Discussion 
Previously, we have demonstrated small GTPase-dependent actin remodeling in SH-SY5Y 
neuroblastoma cells by pneumolysin at sublytic concentrations [22]. When exposing primary rodent 
glial cells (originating from SD rats or C57Bl/6 mice) to 0.1 µg/mL PLY, cell retraction and 
displacement were observed (Figure 1(A), baculovirus-based membrane-GFP live imaging labeling of 
astrocytes). The astrocytic nature of the cells was further verified by an anti-GFAP immunostaining 
(not shown). Detailed analysis demonstrated retraction of individual cells that were adherent to the 
surface, which was accompanied by retraction of processes [Figures 1(A,B)]. In larger astrocyte 
clusters, directional displacement was observed (probably due to accumulation of cell shape changes; 
see Supplementary data S1 and S2 for movies). These effects occurred within 30 minutes after toxin 
challenge. Software tracing of the cell edges (Figure 1(B) shows a tracing example) allowed for 
visualization and measurement of the exact magnitude of cell retraction and displacement. Actin 
depolymerization by cytochalasin D fully inhibited the displacement of the astrocytes after PLY 
exposure [Figure 1(C)].  
Since active cellular retraction and displacement in a given direction should be accompanied by 
changes in the focal adhesion formation and size [34] due to the establishment of traction points, we 
labeled focal adhesions by vinculin immunocytochemistry [35]. Before PLY challenge, the astrocytes 
demonstrated defined, but small focal points, which increased to focal adhesions within 30 min after 
toxin exposure [Figures 2(A,B) (size of adhesions), C (shape of adhesions—more circular (focal 
points] or elongated (focal adhesions)), indicative of RhoA GTPase-like activation and analogous to 
our earlier experimental findings in neuroblastoma cells [22]. The increase in focal adhesion size was 
also inhibited by cytochalasin D pretreatment [Figure 2(B)]. 
These studies helped us to further verify that the cell shape changes represent active cytoskeleton 
reorganizing phenomena without a loss of surface attachment [36]. A model describes the relationship 
between adhesion and motility, which recognizes three states—weak, intermediate and strong adhesion 
state [37] (for a further review see [38]). The presence of focal points in the astrocytes in normal, 
untreated conditions indicated a capacity to be motile. The cell displacement and retraction effects, 
followed by a less motile phase, accompanied by increased adhesion as witnessed by the progression 
from focal points to focal adhesions, fit very well with the concept of a transition from intermediate to 
strong adhesion separated by a motile step. 
All these observations confirm that: (i) Active cytoskeleton (most probably actin) reorganizing 
events follow PLY challenge in primary astroglial cells; and (ii) cell displacement and membrane 
retraction live imaging studies can be used as a reliable and immediately accessible marker for the 
occurrence of actin changes following PLY treatment. This finding is not surprising, because it 
confirms the general knowledge that mammalian cellular motility depends on actin reorganization 
phenomena, as determined by numerous laboratories in the last few decades and excellently reviewed 
by Pollard and Borisy [39], Ridley et al. [40] and Pollard and Cooper [41]. The aim of the current 
work was to only investigate the role of the pore-forming capacity of PLY as an initiation factor for the 
actin cytoskeletal reorganization phenomena, rather than studying in a detail the molecular cascades 
that link PLY and the actin changes. The reason is that toxin-induced actin-reorganizing phenomena in 
glial cells seem to be much more complex than those observed in human neuroblastoma cells, and 
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some non-small GTPase-dependent events might contribute to their occurrence (manuscript in 
preparation). Cell displacement and retraction, in contrast, is a cumulative effect, which can be used as 
a suitable qualitative marker for the capacity of the toxin or its mutant form to initiate cytoskeleton 
reorganizing phenomena.  
Figure 1. Effects of pneumolysin on primary astrocytes. (A) Mouse astrocytes, transduced 
with baculovirus, encoding membrane-targeted GFP, respond with cell shape changes and 
retraction to 0.1 µg/mL PLY. Cell contour outlines indicate time point 0, allowing better 
comparison. (B) Example of cell retraction and cell border tracking following PLY 
challenge. Scale bars: 10 µm. (C) Increased cell displacement by 0.1 µg/mL PLY. Actin 
depolymerization by 4 µM cytochalasin D (CytoD) blocked the PLY-induced changes. 
Circles indicate the tracking starting points. Scale bars: 5 µm. (D) Schematic presentation 
of the displacement—shrinking and deformation, rather than enhanced migration. 
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Figure 2. Induction of focal adhesions following PLY challenge. (A) Immunostaining of 
monolayers of primary astrocytes with phalloidin for F-actin (green) and vinculin antibody 
for focal points/adhesions (red). (B) Increase of focal adhesions size 30 min after challenge 
with 0.1 µg/mL PLY, which is fully inhibited by actin depolymerization following 4 µM 
cytochalasin D (CytoD) exposure. *** p < 0.001 vs. all. Values represent mean ± SEM,  
n = 20–40 cells. (C) Focal adhesion shape change from circular (closer to 1) to elongated 
(closer to 0) following PLY challenge, indicative for a transition from focal points to focal 
adhesions. * p < 0.05, Values represent mean ± SEM, n = 40–60 cells, >5,000 focal points 
analyzed. Scale bar: 10 µm. 
 
 
In our experiments, we always observed the presence of dose-dependent cell lysis. Since PLY is a 
cytolysin, we decided to precisely define the terms lytic/sublytic/non-lytic concentrations in our system 
in order to be able to interpret our findings correctly. We performed live imaging analysis of primary 
glial cultures in the presence of propidium iodide (PI), using PLY concentrations in the range of 0.05 
and 0.5 µg/mL. Simultaneous staining with PI allowed for exclusion of all permeabilized cells. PI 
staining is suitable for discriminating acutely lytic from non-lytic cells [42], but also cells with 
―classical‖ PLY membrane pores (with a size of ~260 Å) should be easily PI-permeable (MW 650) [22]. 
Nevertheless, we have no firm evidence that PI could penetrate sufficiently fast through individual 
macropores to stain the chromatin. Furthermore, the possibility of transient macropore formation could 
not be excluded (and we doubt whether such transient pores might suffice to mediate PI penetration 
into the cytosol), therefore, we limited our definitions to lytic (permeabilized) and non-lytic 
(non-permeabilized) cell populations. The permeabilization of the cells occurred in an exponential 
manner and reached a plateau at all concentrations no later than 40 min after PLY challenge 
[Figure 3(A)]. As the concentration of PLY rose, the half-time of cell permeabilization dropped  
from ~22 min (0.05 µg/mL) to ~6 min (0.5 µg/mL). As soon as the plateau was reached, two defined 
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populations of cells, permeabilized (PI-positive; accounting for about 10% of cells at 0.1 µg/mL PLY) 
and non-permeabilized (~90% of the cells at 0.1 µg/mL PLY), were formed and remained unchanged 
with the time. In all further experiments, we analyzed only the effects of PLY on the non-permeabilized 
cells. Most permeabilized cells belonged to the microglial type, and were clearly distinguishable on the 
top of the astrocyte monolayer in mixed cultures [Figure 3(B), arrows]. All permeabilized cells 
demonstrated a lack of motility, a rounded morphology of the cell body, and a pyknotic rounded 
nucleus shape [Figure 3(C)]. Since the baculovirus transduction works only with astrocytes (but not 
microglia) and most of the lysed cells were microglia, virtually all GFP-positive cells in Figure 1 
should be considered intact. When challenging cells with 0.5 µg/mL PLY, however, many of the 
astrocytes in the monolayer were also permeabilized and demonstrated a rounded cellular morphology 
without processes [Figure 3(D)], and were clearly different from the motile astrocytes under the 
influence of the toxin. We also excluded the existence of transient lytic pores by using a sequential 
staining of the nuclei with PI and YOYO-1 (a green chromatin stain), and showed that cells, once 
permeabilized, remained permeable without a reversal of the permeabilization status (not shown). We 
have also analyzed the possibility that the lytic changes in some of the cells release bioactive 
components that induced cell shape changes in the rest of the astrocytes. For this purpose, we treated 
glial cells with high lytic amounts of PLY, collected the medium, inactivated the toxin by short 
exposure to cholesterol [22] and challenged fresh new glial cell preparations with this medium under 
live imaging conditions. None of the cells that were exposed to the lytic products of the lysed glial 
cells demonstrated retraction, increased motility or changes in cell shape, as seen in cells treated with 
pneumolysin (not shown). Thus, one could speculate that in non-lytic conditions, PLY induces partial 
displacement and retraction, followed by an increase of focal adhesion formation.  
Whereas the role of lytic pores in actin-dependent cell displacement effects could be excluded, it 
remained unclear whether pore formation is needed at all. Evidence exists that PLY builds a 
heterogeneous population of pores, many of which have ion channel properties [43]. All these 
experiments, however, utilize PLY concentrations in a range exceeding the pathophysiologically 
relevant concentrations of PLY (up to 0.2 µg/mL in meningitis [19]) by a factor of 10 or more.  
Thus, we approached this obstacle by characterizing in detail the behavior of PLY at concentrations up 
to 0.2 µg/mL, which were entirely within the disease-relevant range, and by utilizing some non-lytic 
PLY mutant forms, W433F-PLY and delta6-PLY [16,17]. The mutants are known to be strongly 
deficient or completely incapable in their pore forming capacity: W433F-PLY shows 1% of wild-type 
lytic capabilities and delta6-PLY is completely non-lytic (see Introduction). Both mutants bound cell 
membranes in a manner similar to WT-PLY [Figure 4(A)], which was further confirmed by 
biochemical spectrophotometric cholesterol-binding experiments [Figure 4(B)]. The binding capacity 
however, was not completely equal among the pneumolysin forms, therefore the concentration of the 
mutants was adjusted in all further experiments to fit exactly the WT-PLY binding. As expected, none 
of the mutants was lytic in the range of 0.1 to 0.5 µg/mL [Figure 4(C)]. Earlier experiments in artificial 
membranes and cell membrane patches show that W433F-PLY form big (presumably lytic) pores at a 
concentration of 5 µg/mL and more [43,44]. However, these concentrations exceeded those that we 
used in our experiments.  
In primary glial cell cultures treated with non-lytic concentrations of PLY, the toxin induced 
membrane depolarization [Figure 4(D)]. Membrane polarity was analyzed using the oxonol dye 
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DiBac4(5). This dye does not cause mitochondrial uncoupling and shows a linear fluorescence versus 
membrane penetration relationship [45]. The dye’s fluorescence increases when interacting with 
intracellular proteins and preferably with hydrophobic binding sites. Since PLY pores are known to be 
predominantly cation conductive [16,43,44], the occurrence of membrane depolarization implies a role 
of sodium and/or Ca influx. We cannot exclude the possibility, however, that membrane depolarization 
is not due to direct effects of the PLY pores but to the involvement of endogenous ion channels as 
previously suggested [22]. 
Consistent with the depolarization experiments, we tested the conductance across the membrane 
after challenge with WT-PLY, W433F-PLY and delta6-PLY in a PLB as described before [33].  
Only the WT-PLY was capable of forming big pores (corresponding most likely to lytic pores)  
[Figure 4(E), arrow]. Smaller oscillations (up to 25 pA at 170 mV) were also observed, which 
indicated an activity on the artificial membrane. Small conductance oscillations (not bigger than 5 pA 
at 170 mV) were seen with the W433F-PLY mutant, although much smaller and infrequent than with 
WT-PLY at an equivalent toxin concentration [Figure 4(D)]. The treatment with the delta6-PLY 
mutant did not cause any conductance change across the membrane, i.e., no pore-forming capacity was 
present. We could not witness the presence of micropores by W433F-PLY, as defined before [43], 
which could be explained by the much lower concentrations of the toxin we used and the presence of 
cholesterol in the PLB.  
Figure 3. Analysis of the permeabilized/non-permeabilized cells. (A) Permeabilization 
curves of primary mouse astrocytes following challenges with different concentrations of 
PLY as judged by PI chromatin staining. Values represent mean ± SEM, n = 3 
experiments. (B) Microglia (arrows) represent nearly all of the permeabilized cells in a 
primary glial culture. Scale bar: 20 µm. (C) Permeabilized cells are round and immobile, 
with pyknotic nucleus. Scale bar: 10 µm. (D) Cell death and rounding in astrocytes 
following a challenge with lytic 0.5 µg/mL. Scale bar: 20 µm.  
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Figure 4. Membrane binding and pore formation capacity of PLY variants. (A) Western 
blot analysis of the membrane binding of the PLY variant at similar protein concentration. 
The binding difference was adjusted in all further experiments to achieve equivalent 
membrane toxin load (WT—WT-PLY, d6—delta6-PLY, W433F—W433F-PLY). 
(B) Spectrophotometric analysis of the tryptophan fluorescence of the PLY variants before 
and after incubation with cholesterol (chol), demonstrating membrane binding. (C) LDH 
release after exposure of primary astrocytes to 0.5 µg/mL WT-PLY and equivalent 
concentrations of the toxin variants for 30 min. Values represent mean ± SEM (n = 3 
experiments). (D) Membrane polarity change (as judged by the fluorescence intensity of 
DiBAC4(5)) following exposure to 0.1 µg/mL toxin. The graph is representative of 5 
experiments. (E) Analysis of the electric conductance in planar lipid bilayer membranes 
after challenge with 0.3 µg/mL WT-PLY and equivalent concentrations of the toxin 
variants at a voltage of 70 mV. An arrow demonstrates the strong staircase-like increase of 
the conductance following the formation of big pores in the WT-PLY experiment, missing 
in the mutants. 
 
 
Following the characterization of the WT-PLY and the mutants, we tested the ability of the 
non-pore-forming mutants to cause cell shape changes in astrocytes. Both W433F-PLY and  
delta6-PLY mutants failed to cause any shape change or retraction in primary astrocytes, even at 
concentrations exceeding the WT-PLY concentration by up to five-fold (Figure 5). Thus, although the 
effects of PLY affected a non-lytic population of cells, the lytic pore formation capacity remained 
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critically important for inducing cytoskeletal cell shape changes. The possible mechanistic explanation 
could be limited to the formation of transient macropores, micropores (non-lytic pores with  
ion-channel-like features) or to non-pore-related molecular interactions that require the molecular 
conformation capacity of PLY.  
Figure 5. Cell displacement and retraction following exposure to PLY variants. Primary 
astrocytes demonstrated retraction and displacement only after exposure to 0.1 µg/mL  
WT-PLY, but not when challenged with an equivalent amount of the mutant variants  
(WT—WT-PLY, d6—delta6-PLY, W433F—W433F-PLY). Cells are incubated in the 
presence of propidium iodide, which detects permeabilization in few cells, but not in the 
retracted ones. *** −p < 0.001 vs. all other groups. Values represent mean ± SEM,  
n = 40–60 cells of 4 experiments. The red line in the graph indicates automatic stage 
repositioning shift. Scale bars: 10 µm. 
 
 
The evidence for membrane depolarization required studying its possible role as a causative link 
between toxin pores and cytoskeletal changes. Membrane depolarization is capable of activating small 
GTPases in eye epithelial cells [46] and modulating the actin cytoskeleton via a Rho/ROCK signaling 
cascade in airway smooth muscles [47]. The actin-binding protein profilin I increases its colocalization 
with actin in neurons following membrane depolarization [48]. The actin-associated alpha-fodrin, 
capable of mediating actin reorganization, changes its submembranous distribution after membrane 
depolarization in secretory cells [49]. Membrane depolarization could be experimentally achieved by 
an excessive potassium (K) exposure. We incubated primary astrocytes with 50 mM K to cause rapid 
membrane depolarization [Figure 6(A)]. We observed retraction/displacement of the cells following K 
exposure [Figure 6(A)]. Analysis of GFP-stained cells (Supplementary data S4) also demonstrated the 
occurrence not only of cell retraction, but also of generally increased membrane/cell border dynamics 
compared with mock-treated cells (Supplementary data S3). Although membrane depolarization per se 
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could obviously alter cellular kinetics, we needed to provide direct evidence of whether membrane 
depolarization could initiate the actin-dependent cell shape changes by PLY in astrocytes. For this 
purpose, we exposed glial cells to 200 mM sucrose to induce membrane hyperpolarization [31]. We 
verified this by DiBAC4(5) live imaging. Indeed, five minutes after exposure to 200 mM sucrose, the 
membrane polarity increased [Figure 6(B)]. We incubated the hyperpolarized cells with 0.1 µg/mL 
PLY and observed again toxin-induced cell displacement and retraction, not present in the control 
sucrose-conditioned cells [Figure 6(C)]. Notably, the motility difference (as shown of the graph) 
between sucrose-free and sucrose-treated cultures in the presence of PLY is not indicative of a 
difference in response, rather a difference in cell density because the data stem from different cultures. 
Essential in these tests is the comparison with the corresponding controls, which are prepared and 
visualized simultaneously with the PLY-treated cultures (see Methods). Although hyperpolarized, the 
sucrose-pretreated astrocytes demonstrated a certain level of depolarization (not exceeding the 
background polarity of the cells before sucrose application) following PLY challenge, which followed 
exactly the same depolarization curve in amplitude and shape as the PLY-challenged cells without 
sucrose. This result suggests that, in the presence of sucrose, membrane pore formation by the toxin 
remains relatively unchanged. In our experimental system, we mimicked membrane depolarization by 
high K; however, in a real experimental environment membrane depolarization is normally induced by 
sodium (as well as small amounts of Ca) influx. Potassium-selective pores would allow K-efflux and 
hyperpolarization under toxin influence, which is not the case in the glial experimental system, thus 
excluding high K selectivity. Thus, although our membrane hyperpolarization experiments confirmed 
that membrane depolarization alone was not an initiator of cell displacement and retraction, we could 
not exclude that it might play a modulatory role in the cytoskeletal reorganization effects. This could 
be of special importance in the context of the central nervous system, where bioelectrical phenomena 
have profound effects on the crosstalk glia/neurons [50]. Next, we replaced sodium chloride in the 
imaging buffer with equimolar tetramethylammonium chloride (thus preserving the osmolarity), 
eliminating sodium as an influx factor. Again, PLY was able to induce clear displacement and cell 
shape changes in the astrocytes despite the lack of extracellular sodium [Figure 6(D)].  
Since ion influx via ion-selective pores should be accompanied by water influx too, we exposed 
glial cells to hypotonic medium after 50% reconstitution with distilled water. None of the cells 
demonstrated any change in shape, motility or the occurrence of cell displacement, which excluded the 
role of water influx and swelling alone as a possible cell shape change inductor (not shown). 
The ion selectivity of PLY micropores, derived from experiments with PLBs, indicates relative 
cation selectivity and sensitivity against closure by bivalent ions such as Ca and zinc (―small‖ pores). 
PLY alone is known to produce an increase in cellular Ca [27], thus Ca-selective micropores should be 
additionally considered, assuming that they exist and play a role in plasma Ca elevation. Local increase 
of cytosolic Ca is a factor, contributing to cellular motility in electrical field stimulation model 
systems, which partially resembles the effects of PLY on membrane electrical phenomena [51,52]. The 
major source of Ca influx in cells after PLY challenge is the extracellular environment [27], although 
Ca influx from intracellular stores, the biggest of which is the endoplasmic reticulum (ER) [53], should 
be also considered. We have shown that in the human SH-SY5Y neuroblastoma cell line, the activation 
of Rac1 (but not of RhoA) by PLY is dependent on Ca influx [22]. Such an experimental setup, 
however, excludes the role of intracellular Ca depots, thus making it difficult to judge the role of Ca 
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influx in the initiation of cell shape changes. To answer the question about the initiation role of Ca 
influx in PLY-induced cell shape changes, we tested the role of PLY on astrocytes in Ca-free medium 
after an additional depletion of the intracellular Ca stores by 3 µM thapsigargin (an inhibitor of the ER 
Ca
2+
 ATPase), as described by Ubl and Reiser [54]. Such a combination allows a smooth, but  
long-lasting cell Ca depletion without reducing the normal cytosolic Ca level (e.g., as done by BAPTA 
and other Ca chelators), thus maintaining it at a concentration needed for normal functioning of the 
cytoskeleton and associated myosins and just blocking its provisional increase [32]. Following PLY 
exposure, strong cellular displacement was initiated (Figure 7), thus providing evidence that Ca influx 
either from extra- or intracellular depots alone is not responsible for the initiation of these cellular 
changes. The mock-treated astrocytes in Ca-free buffer conditions, however, also demonstrated 
slightly increased motility (Figure 7), which is consistent with the evidence for modulation of the 
function and structure of extracellular adhesion molecules, such as E-cadherin, by Ca [55].  
Figure 6. Effects of membrane depolarization on the PLY-induced cell retraction and 
displacement. (A) Membrane depolarization by 50 mM potassium leads to increased cell 
retraction within 30 min. *** p < 0.001. Values represent mean ± SEM, n = 20–30 cells  
of 3 experiments. (B) Changes in membrane depolarization (as assessed by the DiBac4(5) 
fluorescent intensity change) following 0.1 µg/mL PLY challenge in primary astrocytes 
with and without pretreatment with 200 mM sucrose as a hyperpolarizing agent. Values 
represent mean ± SEM, n = 3 experiments. (C) Cell retraction and displacement effects 
following 0.1 µg/mL PLY exposure, with and without membrane hyperpolarization by 
sucrose, remain. *** p < 0.001. Values represent mean ± SEM, n = 30–40 cells of 3 
experiments. Scale bars: 5 µm. The red line in the graphs indicates automatic stage 
repositioning shift. (D) Cell displacement following 0.1–0.2 µg/mL PLY exposure in 
sodium-free conditions (TMAC replacement) remains. *** p < 0.001. Values represent 
mean ± SEM, n = 60–80 cells of 4 experiments. 
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Figure 7. Cell displacement and retraction in Ca-free conditions. 0.1 µg/mL PLY produces 
cell retraction and displacement in Ca-free buffer conditions and intracellular Ca depot 
depletion by 3 µM thapsigargin. *** p < 0.001. Values represent mean ± SEM, n = 30–40 
cells of 3 experiments. The red line in the graph indicates automatic stage repositioning 
shift. Scale bar: 5 µm. 
 
 
In summary, our work provides evidence for the critical importance of the pore formation capacity 
of PLY in cell shape changes, cell retraction and displacement in non-lytic conditions. Although we 
did not find evidence to support the mechanistic role of the membrane depolarization and the Ca influx 
as pore-related cell shape change initiation factors, we could not exclude their modulatory role in the 
cellular motility effects following the initial PLY challenge. The binding to membrane cholesterol, 
with or without the formation of toxin clusters, however, did not suffice for producing cell shape 
changes when tested with the non-lytic mutants. We cannot exclude the possibility that other pore 
formation-related factors play a role in the actin cytoskeleton effects of PLY. One possibility is the 
interaction with plasmalemmal molecules or with molecules positioned immediately under the 
membrane, the interactions of which would require the toxin molecules to be in a folded pore-like 
conformational state, thus explaining the need for pore-forming capacity. Further work is needed to 
clarify these issues.  
The possible explanation of the pathogenic role of these cell shape changes goes beyond the scope 
of this paper. Nevertheless, one could speculate that cell retraction and displacement, followed by 
increased adhesion, interferes with the important role of the astrocytes in efficiently isolating the brain 
tissue from the pathogens as a component of the blood-brain barrier.  
Although many bacterial toxins possess the feature of modulating actin cytoskeleton dynamics, 
mostly via small GTPase activation or inhibition [21], hardly any of these toxins possesses pore 
forming capacity. Our finding of small GTPase activation via PLY in human neuroblastoma cells [22] 
suggested a possible role not only of pore formation but also of cholesterol sequestration and others. 
Here we provide evidence that the pore forming capacity remains essential for rapid cytoskeletal 
reorganization, implying that PLY pore formation might play a much more complex role in the 
modulation of pathogen virulence than previously expected. 
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4. Conclusions 
The cholesterol-dependent cytolysin pneumolysin, a major pathogenic factor of S. pneumoniae, 
produced massive cell shape changes and cell retraction in primary astrocytes. These changes occurred 
in non-lytic conditions, but nevertheless required the pore-forming capacity of PLY. The effects were 
largely independent of cellular ion flux phenomena and implied the existence of a more complex 
toxin/membrane/cytoskeleton interaction mechanism, in which an intact molecular pore-forming 
capacity remains essential without being necessarily related to pore formation.  
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